All HHS Contracts — September 23, 2026

Regeneron’s $278.8 million cost-sharing contract from HHS/BARDA has already seen $236.3 million outlayed, implying 85% execution and strong near-term cash flow. The contract’s potential value of $359.6 million through 2027 provides multi-year revenue visibility.

The contract has a potential value of $359.6 million, meaning $80.8 million in unexercised options remain. Exercise of these options would represent a 29% upside to the current obligation and signal sustained BARDA commitment.

BARDA’s budget and policy priorities may shift under a new administration, potentially affecting option exercises or follow-on contracts for Regeneron’s $278.8M award. The cost-sharing structure also limits profit margins compared to fixed-price contracts.

This single contract represents 100% of the digest’s total value and is concentrated in one company (Regeneron) and one agency (HHS/BARDA). Any disruption to this contract would have outsized impact on the digest’s narrative.

Regeneron’s expertise in monoclonal antibodies positions it for follow-on BARDA contracts in pandemic preparedness and biodefense, especially given the $80.8 million in unexercised options and the contract’s 10-year duration through 2027.

The contract signals HHS/BARDA’s continued prioritization of biotechnology R&D for public health emergencies, creating opportunities for other biotech firms (e.g., Moderna, GSK) in similar cost-sharing arrangements.

Regeneron’s $278.8M BARDA contract, with $236.3M already outlayed, demonstrates the government’s long-term commitment to biotechnology R&D for public health emergencies, even outside of acute pandemic periods.

{"entity" => "Regeneron Pharmaceuticals", "reason" => "The $278.8M contract has $80.8M in unexercised options and $236.3M already outlayed, making option exercises and revenue recognition key near-term catalysts.", "trigger" => "Option exercise announcement or quarterly filing showing revenue from this contract"}

{"entity" => "BARDA", "reason" => "As the awarding agency, BARDA’s budget and policy shifts directly impact Regeneron’s contract value and potential follow-ons.", "trigger" => "FY2027 HHS budget release or new BARDA director appointment"}